Vaxxas Inc.
47 Thorndike Street, Suite B1-1
Cambridge
Massachusetts
02141
United States
Website: http://www.vaxxas.com/
Email: dhoey @ vaxxas.com
23 articles about Vaxxas Inc.
-
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
11/26/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch, instead of using traditional needle and syringe.
-
Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)
10/18/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”
-
SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine
8/24/2023
SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.
-
Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch
8/24/2023
Vaxxas announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.
-
Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products
6/18/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland.
-
Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)
6/5/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
-
Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
6/5/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.
-
Ease-of-Use and Potential Self-Administration of Vaccination Shown with Vaxxas High Density Microarray Patch (HD-MAP)
3/30/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration.
-
Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent (IIV4) Delivered Using High-Density Microarray Patch (HD-MAP)
2/9/2023
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
-
Coming in From the Cold: Needle-free Patch Technology for Mrna Vaccines Aims to End Need for Frozen Storage and Improve Access
1/17/2023
CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project that could end the need for frozen storage of mRNA vaccines.
-
Vaxxas Appoints Doug Cubbin as Chief Financial Officer
12/1/2022
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, announced another key addition to its executive leadership team with the appointment of Doug Cubbin as Chief Financial Officer.
-
Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)
11/8/2022
Vaxxas holds an exclusive license from The University of Texas at Austin (UTA) to the SARS-CoV-2 spike subunit vaccine (HexaPro) for vaccination using a patch.
-
Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer
4/20/2022
Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer.
-
Vaxxas Announces Appointment of Dan Devine as Chief Business Officer and General Counsel
4/13/2022
Vaxxas is pleased to announce a key appointment to its executive leadership team aimed at facilitating the company’s continued and accelerating growth.
-
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
-
Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
6/2/2021
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal model Complete protection from COVID-19 disease by a single dose skin patch delivery using Vaxxas’ HD-MAP was demonstrated in a lethal challenge of the SARS-COV-2 virus in an animal model
-
Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
10/5/2020
Needle-free Vaxxas HD-MAP patch offers potential platform to dramatically improve vaccination in pandemic response by producing more patient-doses from limited quantities of vaccine, enabling rapid vaccine distribution without refrigeration, and creating a novel option for self-administration. Initial BARDA funding focuses on clinical demonstration using pandemic influenza vaccine; Vaxxas investigating opportunities to improve performance of other
-
Vaxxas Announces That Merck Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
5/28/2020
Vaxxas Announces That Merck Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
-
Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial-scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD-MAP)
5/28/2020
Needle-free Vaxxas HD-MAP can enhance routine vaccination with potential to revolutionize vaccination in pandemic response; produce more patient-doses from limited quantities of vaccine, distribution without refrigeration, and potential for self-administration.
-
Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study of Measles and Rubella Vaccination using Vaxxas’ High Density Micro-Array Patch
3/17/2020
Funding Accelerates Vaxxas’ Clinical Pipeline of Innovative Vaccines